FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313509563> ?p ?o ?g. }

• W4313509563 endingPage "358" @default.
• W4313509563 startingPage "358" @default.
• W4313509563 abstract "Outcomes and prognostic factors of second-line gemcitabine plus nab-paclitaxel (GnP) after modified FOLFIRINOX (mFFX) for unresectable pancreatic cancer were unclear. We retrospectively analyzed consecutive patients with unresectable pancreatic cancer treated with GnP after first-line mFFX treatment between March 2015 and March 2022 at our hospital. A total of 103 patients were included. Median overall survival (OS) from the start of first-line and second-line treatments was 14.9 months and 7.2 months, respectively. Median progression-free survival (PFS) was 3.6 months. Performance status, modified Glasgow prognostic score, and neutrophil-to-lymphocyte ratio were independently associated with OS. Our prognostic model using these parameters classifies patients into good (n = 70) and poor (n = 33) prognosis groups. Median OS and PFS were longer in the good prognosis group than in the poor prognosis group (OS: 9.3 vs. 3.8 months, p < 0.01; PFS: 4.1 vs. 2.3 months, p < 0.01). Grade 3/4 adverse events were observed in 70.9% of patients, with neutropenia being the most frequent. While GnP as second-line treatment was well-tolerated, efficacy of second-line gemcitabine plus nab-paclitaxel was notably limited, particularly in the poor prognosis group." @default.
• W4313509563 created "2023-01-06" @default.
• W4313509563 creator A5000489992 @default.
• W4313509563 creator A5003171350 @default.
• W4313509563 creator A5003195457 @default.
• W4313509563 creator A5004340414 @default.
• W4313509563 creator A5010319344 @default.
• W4313509563 creator A5021509769 @default.
• W4313509563 creator A5024020058 @default.
• W4313509563 creator A5024647452 @default.
• W4313509563 creator A5039269495 @default.
• W4313509563 creator A5050881417 @default.
• W4313509563 creator A5066075096 @default.
• W4313509563 creator A5067201661 @default.
• W4313509563 creator A5070620598 @default.
• W4313509563 date "2023-01-05" @default.
• W4313509563 modified "2023-09-26" @default.
• W4313509563 title "Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer" @default.
• W4313509563 cites W1984052587 @default.
• W4313509563 cites W1984356383 @default.
• W4313509563 cites W2019607817 @default.
• W4313509563 cites W2121960517 @default.
• W4313509563 cites W2141087037 @default.
• W4313509563 cites W2151253787 @default.
• W4313509563 cites W2165480504 @default.
• W4313509563 cites W2187917981 @default.
• W4313509563 cites W2198085515 @default.
• W4313509563 cites W2345269414 @default.
• W4313509563 cites W2472707660 @default.
• W4313509563 cites W2481516632 @default.
• W4313509563 cites W2591717879 @default.
• W4313509563 cites W2607635805 @default.
• W4313509563 cites W2768254225 @default.
• W4313509563 cites W2790828570 @default.
• W4313509563 cites W2897046116 @default.
• W4313509563 cites W2906440375 @default.
• W4313509563 cites W2946882971 @default.
• W4313509563 cites W2976165418 @default.
• W4313509563 cites W3006638330 @default.
• W4313509563 cites W3026526879 @default.
• W4313509563 cites W3032454272 @default.
• W4313509563 cites W3153757567 @default.
• W4313509563 cites W3157124324 @default.
• W4313509563 cites W3167070566 @default.
• W4313509563 cites W3186321460 @default.
• W4313509563 cites W3197559541 @default.
• W4313509563 cites W3211913303 @default.
• W4313509563 cites W4226185856 @default.
• W4313509563 cites W4281697199 @default.
• W4313509563 cites W4296033043 @default.
• W4313509563 doi "https://doi.org/10.3390/cancers15020358" @default.
• W4313509563 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36672308" @default.
• W4313509563 hasPublicationYear "2023" @default.
• W4313509563 type Work @default.
• W4313509563 citedByCount "0" @default.
• W4313509563 crossrefType "journal-article" @default.
• W4313509563 hasAuthorship W4313509563A5000489992 @default.
• W4313509563 hasAuthorship W4313509563A5003171350 @default.
• W4313509563 hasAuthorship W4313509563A5003195457 @default.
• W4313509563 hasAuthorship W4313509563A5004340414 @default.
• W4313509563 hasAuthorship W4313509563A5010319344 @default.
• W4313509563 hasAuthorship W4313509563A5021509769 @default.
• W4313509563 hasAuthorship W4313509563A5024020058 @default.
• W4313509563 hasAuthorship W4313509563A5024647452 @default.
• W4313509563 hasAuthorship W4313509563A5039269495 @default.
• W4313509563 hasAuthorship W4313509563A5050881417 @default.
• W4313509563 hasAuthorship W4313509563A5066075096 @default.
• W4313509563 hasAuthorship W4313509563A5067201661 @default.
• W4313509563 hasAuthorship W4313509563A5070620598 @default.
• W4313509563 hasBestOaLocation W43135095631 @default.
• W4313509563 hasConcept C121608353 @default.
• W4313509563 hasConcept C126322002 @default.
• W4313509563 hasConcept C143998085 @default.
• W4313509563 hasConcept C2776694085 @default.
• W4313509563 hasConcept C2776907518 @default.
• W4313509563 hasConcept C2777063308 @default.
• W4313509563 hasConcept C2777148230 @default.
• W4313509563 hasConcept C2777292972 @default.
• W4313509563 hasConcept C2780210213 @default.
• W4313509563 hasConcept C2780258809 @default.
• W4313509563 hasConcept C2780259306 @default.
• W4313509563 hasConcept C2780739268 @default.
• W4313509563 hasConcept C526805850 @default.
• W4313509563 hasConcept C71924100 @default.
• W4313509563 hasConcept C90924648 @default.
• W4313509563 hasConceptScore W4313509563C121608353 @default.
• W4313509563 hasConceptScore W4313509563C126322002 @default.
• W4313509563 hasConceptScore W4313509563C143998085 @default.
• W4313509563 hasConceptScore W4313509563C2776694085 @default.
• W4313509563 hasConceptScore W4313509563C2776907518 @default.
• W4313509563 hasConceptScore W4313509563C2777063308 @default.
• W4313509563 hasConceptScore W4313509563C2777148230 @default.
• W4313509563 hasConceptScore W4313509563C2777292972 @default.
• W4313509563 hasConceptScore W4313509563C2780210213 @default.
• W4313509563 hasConceptScore W4313509563C2780258809 @default.
• W4313509563 hasConceptScore W4313509563C2780259306 @default.
• W4313509563 hasConceptScore W4313509563C2780739268 @default.
• W4313509563 hasConceptScore W4313509563C526805850 @default.

• next